Iron oxide nanoparticles: a versatile nanoplatform for the treatment and diagnosis of ovarian cancer.

Ovarian cancer remains one of the main causes of human mortality, accounting for millions of deaths every year. Despite of several clinical options such as chemotherapy, photodynamic therapy (PDT), hormonal treatment, radiation therapy, and surgery to manage this disease, the mortality rate is still very high. This alarming statistic highlights the urgent need for innovative approaches to improve both diagnosis and treatment. Success stories of iron oxide nanoparticles, i.e. Ferucarbotran (Resovist®) and Ferrixan (Cliavist®) for liver imaging, CNS (Central nervous system) imaging, cell labeling, etc. have motivated researchers to explore these nanocarriers for treatment and diagnosis of different diseases. Iron oxide nanoparticles have improved the therapeutic efficacy of anticancer drugs through targeted delivery, heat/ROS (reactive oxygen species) generation on application of external energy and have also shown great potential as contrast agents for magnetic resonance imaging (MRI). Their unique magnetic properties enable sensitive imaging, and surface modification allows the attachment of specific biomolecules for targeted detection of ovarian cancer cells. Their unique properties, . magnetic responsiveness and surface functionalization, make them versatile tools for enhancing both imaging and therapeutic outcomes. Present article reviews the literature on the synthesis, functionalization, and applications of iron oxide nanoparticles in management of ovarian cancer.